The genetic determinants of atorvastatin response

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 6, 2007, Pages 545-553

  Rodrigues, A C ^a   Hirata, M H ^a   Hirata, R D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atorvastatin; Pharmacogenetics; Pharmacogenomics; Polymorphisms

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIET; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; ENZYME INHIBITOR INTERACTION; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIVER FUNCTION; MYALGIA; MYOPATHY; PHARMACOGENETICS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MUSCULAR DISEASES; PYRROLES; RISK FACTORS; VARIATION (GENETICS);

EID: 36549071137     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc (1986) 256(20):2823-2828.
2. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res (1992) 33(11):1569-1582.
3. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232(4746):34-47.
4. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc (1996) 275(2):128-133.
5. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol (2000) 35(1):1-10.
6. Stancu C, Sima A: Statins: Mechanism of action and effects. J Cell Mol Med (2001) 5(4):378-387.
7. Liao JK: Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol (2002) 86(1):5-18.
8. Maitland-van der Zee AH, Boerwinkle E: Pharmacogenetics of response to statins: Where do we stand? Curr Atheroscler Rep (2005) 7(3):204-208.
9. Roden DM, George AL Jr: The genetic basis of variability in drug responses. Nat Rev Drug Discov (2002) 1(1):37-44. • This review discusses the concept that genetic variants might determine much of the variability in drug response, and proposes an algorithm to enable further evaluation of the benefits and pitfalls of this enticing possibility.
10. Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ: Pharmacogenetics of HMG-CoA reductase inhibitors: Exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis (2004) 177(2):219-234.
11. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MS, Sasiela WJ: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J (2005) 5(6):352-358. • This is the largest study associating genes and atorvastatin response. It is of interest because it is a replication study. Associations previously reported between genotype and statins were tested for reproducibility.
12. Mahley RW, Rall SC Jr: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet (2000) 1:507-537.
13. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM: Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis (2001) 158(1):183-193.
14. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS: The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther (2006) 11(3):211-221.
15. Garcia-Otin AL, Civeira F, Aristegui R, Diaz C, Recalde D, Sol JM, Masramon X, Hernandez G, Pocovi M: Allelic polymorphism -491A/T in apoE gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur J Clin Invest (2002) 32(6):421-428.
16. Hasham SN, Pillarisetti S: Vascular lipases, inflammation and atherosclerosis. Clin Chim Acta (2006) 372(1-2):179-183.
17. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R: Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res (2003) 44(12):2374-2381.
18. Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A: A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol (1998) 18(5):756-761.
19. Garcia-Garcia AB, Gonzalez C, Real JT, Martin de Llano JJ, Gonzalez-Albert V, Civera M, Chaves FJ, Ascaso JF, Carmena R: Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet Genomics (2005) 15(4):211-218.
20. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc (2004) 291(23):2821-2827.
21. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J (2006) 6(6):360-374.
22. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M: Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics (2005) 15(4):219-225.
23. Hersberger M, von Eckardstein A: Low high-density lipoprotein cholesterol: Physiological background, clinical importance and drug treatment. Drugs (2003) 63(18):1907-1945.
24. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM: Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care (2003) 26(4):1216-1223.
25. Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ: Gender-specific effects of estrogen receptor α gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: Interaction with apolipoprotein AI gene polymorphism. Atherosclerosis (2005) 178(2):331-338.
26. Sorkin SC, Forestiero FJ, Hirata MH, Guzman EC, Cavalli SA, Bertolami MC, Salazar LA, Hirata RD: APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med (2005) 43(12):1339-1345.
27. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 286(1-2):152-154.
28. Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, Lehtimaki T: Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics (2001) 11(7):625-633.
29. Deakin S, Leviev I, Guernier S, James RW: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol (2003) 23(11):2083-2089.
30. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2000) 20(9):2113-2119.
31. Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M: The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med (2005) 258(5):442-449.
32. Aouizerat BE, Allayee H, Bodnar J, Krass KL, Peltonen L, de Bruin TW, Rotter JI, Lusis AJ: Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol (1999) 10(2):113-122.
33. Cenarro A, Artieda M, Gonzalvo C, Merino-Ibarra E, Aristegui R, Ganan A, Diaz C, Sol JM, Pocovi M, Civeira F: Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. Am Heart J (2005) 150(6):1154-1162.
34. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A, Rivera CR, Mulvihill SJ, Malloy MJ, Kane JP: Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest (2002) 110(1):109-117.
35. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290(5497):1771-1775.
36. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis (2005) 180(2):407-415.
37. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis (2004) 175(2):287-293.
38. Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, Naoumova RP: Atorvastatin affects leukocyte gene expression in dyslipidemia patients: In vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost (2005) 3(4):677-685. • The lipid-lowering independent action of atorvastatin in the regulation of gene expression of hemostasis, inflammation and apoptotic genes in peripheral blood leukocytes, was observed for the first time.
39. Nagassaki S, Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JE: eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res (2005) 115(5):375-379.
40. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE: Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis (2007) 193(2):438-444.
41. Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A, Bruni F: Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest (2005) 35(1):47-51.
42. Puccetti L, Pasqui AL, Pastorelli M, Ciani F, Palazzuoli A, Gioffre W, Auteri A, Bruni F: 3′UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis (2005) 183(2):322-328.
43. Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet (2003) 42(13):1141-1160.
44. Christians U, Schmitz V, Haschke M: Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol (2005) 1(4):641-654.
45. Jacobson TA: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol (2004) 94(9):1140-1146.
46. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther (2005) 78(2):154-167.
47. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstol K: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther (2006) 79(6):532-539. • Patients with atorvastatin-related myopathy exhibited an altered metabolism profile with significantly higher levels of atorvastatin lactone and hydroxylated metabolites.
48. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol (2004) 93(1):104-107.
49. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV et al: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem (1989) 264(18):10388-10395.
50. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 27(4):383-391.
51. Schuetz JD, Beach DL, Guzelian PS: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics (1994) 4(1):11-20.
52. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol (1990) 38(2):207-213.
53. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 14(8):523-525. •• The non-functional allele of CYP3A5 (CYP3A5*3) was associated with a higher response to atorvastatin. This is of interest, as a minority of Caucasians express CYP3A5 and this may be a predictor of poor response to atorvastatin.
54. Ho RH, Kim RB: Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther (2005) 78(3): 260-277.
55. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2007) 315(5811):525-528.
56. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol (2004) 93(8):1046-1050.
57. Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD: High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res (2005) 38(9):1389-1397.
58. Chandra P, Brouwer KL: The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm Res (2004) 21(5):719-735.
59. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem (1999) 274(52):37161- 37168.
60. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W et al: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther (2006) 80(6):607-620.
61. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. J Am Med Assoc (2003) 289(13):1681-1690.
62. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statin-related adverse events: A meta-analysis. Clin Ther (2006) 28(1):26-35. • A meta-analysis study that analyzed the collective adverse effects data observed in clinical trials of all statins.
63. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipidlowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 80(6):565-581.
64. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD: Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics (2000) 10(5):373-388.
65. Wilke RA, Moore JH, Burmester JK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics (2005) 15(6):415-421. •• This is one of the few pharmacogenetic studies of atorvastatin-induced myopathy. These researchers demonstrated that CYP3A5*3 homozygotes experienced a greater degree of muscle damage during atorvastatin treatment.
66. Ruaňo G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR, Seip R, Wu AH: Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics (2005) 6(8):865-872.
67. Schmitz G, Langmann T: Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol (2006) 44(2):75-89.
68. Kajinami K, Akao H, Polisecki E, Schaefer EJ: Pharmacogenomics of statin responsiveness. Am J Cardiol (2005) 96(9A):65K-70K; discussion 34K-35K.
69. Schork NJ, Fallin D, Lanchbury JS: Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet (2000) 58(4):250-264.
70. Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ: ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res (2004) 45(4):653-656.
71. Sposito AC, Gonbert S, Bruckert E, Atassi M, Beucler I, Amsellem S, Khallouf O, Benlian P, Turpin G: Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2003) 23(11):2078-2082.
72. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A: Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin (2005) 21(5):777-784.